AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01529424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2
Trial: NCT01529424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 3
Trial: NCT00882531
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03516669
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
Trial: NCT03516669
Drug: Amoxicillin, Clarithromycin
RxNorm normalized name: Lansoprazole, Amoxicillin, Clarithromycin KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
Trial: NCT00950534
Drug: Oral Anti Diabetics (OAD)
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
Trial: NCT04322396
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin
Trial: NCT04322396
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Azithromycin
Trial: NCT04322396
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Hydroxychloroquine
Trial: NCT00802412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
Trial: NCT03224702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matched to M6495 on Day 1
Trial: NCT03323047
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo 1 hr pre-operatively
Trial: NCT00881946
Drug: GSK21110183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
Trial: NCT04448899
Drug: Blacebo plus standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blacebo plus standard treatment
Trial: NCT02659020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02202447
Drug: EC1169
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.
Trial: NCT02254707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02151448
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
Trial: NCT01163994
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally, 100 mg, bid, 15 days
Trial: NCT00621218
Drug: tretinoin gel 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
Trial: NCT00621218
Drug: vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
Trial: NCT03493490
Drug: Neodolpasse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Trial: NCT03493490
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Trial: NCT03493490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Trial: NCT02941679
Drug: HCP1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hanmi Pharmaceutical. Co., Ltd.
Trial: NCT02941679
Drug: HGP1011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boehringer Ingelheim
Trial: NCT02941679
Drug: HCP0910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GlaxoSmithKline
Trial: NCT02261376
Drug: DS-1971a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
Trial: NCT03075670
Drug: ALPROLIX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 50 IU/kg for intravenous (i.v.) injection
Trial: NCT02325011
Drug: Sativex® (Treatment A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Trial: NCT02519712
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
Trial: NCT00656630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsule, 1 week duration
Trial: NCT01411163
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 30 grams daily creatine monohydrate
Trial: NCT05492669
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
Trial: NCT02273219
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
Trial: NCT02273219
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
Trial: NCT04275596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of topical placebo on the anal wound until complete wound healing
Trial: NCT02321462
Drug: Fortrans®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
Trial: NCT02196324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03571919
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of saline and then infusion
Trial: NCT02635191
Drug: Tailored Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
Trial: NCT02635191
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
Trial: NCT03367377
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02724904
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Bolus
Trial: NCT02265822
Drug: melatonin in children premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01183169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALV placebo soft gel capsules administered orally
Trial: NCT00089570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00692770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 tablets twice daily (BID)
Trial: NCT04321161
Drug: Bicanorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)
Trial: NCT00397800
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00917891
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks
Trial: NCT01889680
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/m2 IV day 1 every 14 days until disease progression
Trial: NCT01889680
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
Trial: NCT01930292
Drug: Part A: Debio 1143
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
Trial: NCT01930292
Drug: Part B: Debio 1143
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
Trial: NCT02258204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00924911
Drug: GSK1322322
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four different formulations of 1000mg of GSK1322322
Trial: NCT00924911
Drug: GSK1322322
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 1000mg
Trial: NCT00454090
Drug: AZD8330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03293654
Drug: MB02
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Trial: NCT03293654
Drug: US licenced Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Trial: NCT00587379
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pill per day
Trial: NCT04494984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
Trial: NCT00819416
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin for the first 7 days of care in the ICU
Trial: NCT00819416
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline for the first 7 days of care in the ICU
Trial: NCT03726177
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Trial: NCT04882007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT03960502
Drug: [13C315N3]AG-881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV microdose of approximately 100 μg.
Trial: NCT03711162
Drug: GLPG1690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1690, film-coated tablets for oral use.
Trial: NCT03711162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, film-coated tablets for oral use.
Trial: NCT02431754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03427359
Drug: cisplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
Trial: NCT01275066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
Trial: NCT02871128
Drug: supplement
RxNorm normalized name: fat supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
Trial: NCT01581463
Drug: Liothyronine, Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 100-microgram (2 X 50 microgram) dose.
Trial: NCT03569371
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB054707 administered once daily orally with water without regard to food for 8 weeks.
Trial: NCT00291122
Drug: celecoxib 400 mg BID
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01344369
Drug: Norethindrone/Ethinyl Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/0.035 mg Chewable Tablets
Trial: NCT01344369
Drug: FEMCON® Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/0.035 mg Chewable Tablets
Trial: NCT03383328
Drug: NSAID + prednisolone, preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
Trial: NCT03383328
Drug: NSAID + prednisolone, postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
Trial: NCT03383328
Drug: NSAID, preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
Trial: NCT03383328
Drug: NSAID, postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
Trial: NCT03383328
Drug: Drop-less surgery
RxNorm normalized name: lesser galangal root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
Trial: NCT04573036
Drug: HRS4800 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration
Trial: NCT04573036
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration
Trial: NCT01641367
Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
Trial: NCT01641367
Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
Trial: NCT01782781
Drug: ropivacaine, ketorelac and epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group
Trial: NCT01782781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group
Trial: NCT01827657
Drug: GSK2336805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
Trial: NCT03237728
Drug: 0.06mg/kg,KB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06mg/kg,Q8h,Day1-Day7
Trial: NCT03237728
Drug: 0.12mg/kg,KB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12mg/kg,Q8h,Day1-Day7
Trial: NCT03237728
Drug: 0.24mg/,KB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24mg/kg,Q8h,Day1-Day7
Trial: NCT03237728
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos,Q8h,Day1-Day7
Trial: NCT02079688
Drug: SB011, 2 % (Water/Oil/Water) emulsion of hgd40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
Trial: NCT02079688
Drug: Multiple W/O/W formulation, active ingredient-free vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
Trial: NCT02686294
Drug: HL151
RxNorm normalized name: Hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug : HL151. 1T, once a day oral administration, for 4 days
Trial: NCT02586493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 1 inhalation once-daily until visit 2.
Trial: NCT00964431
Drug: Celecoxib 400 mg
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules 2 x 200 mg Single-Dose